102 related articles for article (PubMed ID: 22429065)
1. Patient empowerment and optimal glycemic control.
White RD
Curr Med Res Opin; 2012 Jun; 28(6):979-89. PubMed ID: 22429065
[TBL] [Abstract][Full Text] [Related]
2. Dosing of insulin glargine in the treatment of type 2 diabetes.
Barnett A
Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
[TBL] [Abstract][Full Text] [Related]
3. Fine-tuning therapy with basal insulin for optimal glycemic control in type 2 diabetes: a review.
Dailey G
Curr Med Res Opin; 2004 Dec; 20(12):2007-14. PubMed ID: 15701217
[TBL] [Abstract][Full Text] [Related]
4. Minimizing the risk of hypoglycemia in older adults: a focus on long-term care.
Garza H
Consult Pharm; 2009 Jun; 24 Suppl B():18-24. PubMed ID: 19555132
[TBL] [Abstract][Full Text] [Related]
5. Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control.
Robertson C
Diabetes Educ; 2006; 32(3):423-32. PubMed ID: 16772658
[TBL] [Abstract][Full Text] [Related]
6. Insulin therapy in the elderly patient with diabetes.
Tanwani LK
Am J Geriatr Pharmacother; 2011 Feb; 9(1):24-36. PubMed ID: 21459306
[TBL] [Abstract][Full Text] [Related]
7. Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes.
Caballero AE
J Diabetes Complications; 2009; 23(2):143-52. PubMed ID: 18413192
[TBL] [Abstract][Full Text] [Related]
8. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
Baxter MA
Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
[TBL] [Abstract][Full Text] [Related]
9. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
10. When oral agents fail: optimizing insulin therapy in the older adult.
Meece J
Consult Pharm; 2009 Jun; 24 Suppl B():11-7. PubMed ID: 19555131
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.
Yki-Järvinen H
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S77-81. PubMed ID: 12324990
[TBL] [Abstract][Full Text] [Related]
12. A review of inhaled technosphere insulin.
Neumiller JJ; Campbell RK; Wood LD
Ann Pharmacother; 2010; 44(7-8):1231-9. PubMed ID: 20516362
[TBL] [Abstract][Full Text] [Related]
13. Insulin therapy for maximal glycemic control in type 2 diabetes mellitus.
Spellman CW
J Am Osteopath Assoc; 2007 Jul; 107(7):260-9. PubMed ID: 17682113
[TBL] [Abstract][Full Text] [Related]
14. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes.
Ross SA; Tildesley HD; Ashkenas J
Curr Med Res Opin; 2011 Nov; 27 Suppl 3():13-20. PubMed ID: 21942467
[TBL] [Abstract][Full Text] [Related]
15. Feature selection and classification model construction on type 2 diabetic patients' data.
Huang Y; McCullagh P; Black N; Harper R
Artif Intell Med; 2007 Nov; 41(3):251-62. PubMed ID: 17707617
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.
Goldberg RB; Fonseca VA; Truitt KE; Jones MR
Arch Intern Med; 2008 Jul; 168(14):1531-40. PubMed ID: 18663165
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
Ovalle F
Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
[TBL] [Abstract][Full Text] [Related]
18. Initiating insulin in patients with type 2 diabetes.
Aoki TJ; White RD
J Fam Pract; 2007 Aug; 56(8 Suppl Hot Topics):S12-20. PubMed ID: 18667139
[TBL] [Abstract][Full Text] [Related]
19. Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered?
Spollett GR
J Am Acad Nurse Pract; 2012 Apr; 24 Suppl 1():249-59. PubMed ID: 22564101
[TBL] [Abstract][Full Text] [Related]
20. Initiating a glucagon-like peptide-1 receptor agonist in the management of type 2 diabetes mellitus.
Gavin JR
J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S16-21. PubMed ID: 22267299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
